ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for relapsed or refractory B-cell lymphoma.

The post ModeX starts dosing in MDX2003 trial for B-cell lymphoma appeared first on Clinical Trials Arena.